ZD-4190 | CAS#413599-62-9 | VEGFR2 inhibitor

MedKoo Cat#: 462402 | Name: ZD-4190

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

ZD-4190 is a potent, orally available inhibitor of the vascular endothelial cell growth factor receptor 2 (VEGFR2) and of epidermal growth factor receptor (EGFR) signalling, used for the treatment of cancer.

Chemical Structure

ZD-4190

CAS#413599-62-9

Theoretical Analysis

MedKoo Cat#: 462402

Name: ZD-4190

CAS#: 413599-62-9

Chemical Formula: C19H16BrFN6O2

Exact Mass: 458.0502

Molecular Weight: 459.28

Elemental Analysis: C, 49.69; H, 3.51; Br, 17.40; F, 4.14; N, 18.30; O, 6.97

Price and Availability

Size	Price	Availability
5mg	USD 950.00	2 Weeks
10mg	USD 1,400.00	2 Weeks
50mg	USD 3,500.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

ZD-4190; ZD4190; ZD 4190

IUPAC/Chemical Name

7-(2-(1H-1,2,3-triazol-1-yl)ethoxy)-N-(4-bromo-2-fluorophenyl)-6-methoxyquinazolin-4-amine

InChi Key

YBTGTVGEKMZEQX-UHFFFAOYSA-N

InChi Code

InChI=1S/C19H16BrFN6O2/c1-28-17-9-13-16(10-18(17)29-7-6-27-5-4-24-26-27)22-11-23-19(13)25-15-3-2-12(20)8-14(15)21/h2-5,8-11H,6-7H2,1H3,(H,22,23,25)

SMILES Code

BrC(C=C1F)=CC=C1NC2=C3C(C=C(OCCN4C=CN=N4)C(OC)=C3)=NC=N2

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 459.28 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Yang M, Gao H, Yan Y, Sun X, Chen K, Quan Q, Lang L, Kiesewetter D, Niu G, Chen X. PET imaging of early response to the tyrosine kinase inhibitor ZD4190. Eur J Nucl Med Mol Imaging. 2011 Jul;38(7):1237-47. doi: 10.1007/s00259-011-1742-z. Epub 2011 Mar 1. PMID: 21360246; PMCID: PMC3184245. 2: Tazzyman S, Barry ST, Ashton S, Wood P, Blakey D, Lewis CE, Murdoch C. Inhibition of neutrophil infiltration into A549 lung tumors in vitro and in vivo using a CXCR2-specific antagonist is associated with reduced tumor growth. Int J Cancer. 2011 Aug 15;129(4):847-58. doi: 10.1002/ijc.25987. Epub 2011 Apr 13. PMID: 21328342. 3: Gaballah K, Oakley R, Hills A, Ryan A, Partridge M. The antiangiogenic agent ZD4190 prevents tumour outgrowth in a model of minimal residual carcinoma in deep tissues. Br J Cancer. 2009 Aug 4;101(3):418-23. doi: 10.1038/sj.bjc.6605092. Epub 2009 Jul 21. PMID: 19623179; PMCID: PMC2720249. 4: Morrison MS, Ricketts SA, Barnett J, Cuthbertson A, Tessier J, Wedge SR. Use of a novel Arg-Gly-Asp radioligand, 18F-AH111585, to determine changes in tumor vascularity after antitumor therapy. J Nucl Med. 2009 Jan;50(1):116-22. doi: 10.2967/jnumed.108.056077. Epub 2008 Dec 17. PMID: 19091899. 5: Brochot C, Bessoud B, Balvay D, Cuénod CA, Siauve N, Bois FY. Evaluation of antiangiogenic treatment effects on tumors' microcirculation by Bayesian physiological pharmacokinetic modeling and magnetic resonance imaging. Magn Reson Imaging. 2006 Oct;24(8):1059-67. doi: 10.1016/j.mri.2006.04.002. Epub 2006 May 23. PMID: 16997076. 6: Nguyen QD, Rodrigues S, Rodrigue CM, Rivat C, Grijelmo C, Bruyneel E, Emami S, Attoub S, Gespach C. Inhibition of vascular endothelial growth factor (VEGF)-165 and semaphorin 3A-mediated cellular invasion and tumor growth by the VEGF signaling inhibitor ZD4190 in human colon cancer cells and xenografts. Mol Cancer Ther. 2006 Aug;5(8):2070-7. doi: 10.1158/1535-7163.MCT-06-0044. PMID: 16928828. 7: Lloyd PG, Prior BM, Li H, Yang HT, Terjung RL. VEGF receptor antagonism blocks arteriogenesis, but only partially inhibits angiogenesis, in skeletal muscle of exercise-trained rats. Am J Physiol Heart Circ Physiol. 2005 Feb;288(2):H759-68. doi: 10.1152/ajpheart.00786.2004. Epub 2004 Oct 7. PMID: 15471974. 8: Pradel C, Siauve N, Bruneteau G, Clement O, de Bazelaire C, Frouin F, Wedge SR, Tessier JL, Robert PH, Frija G, Cuenod CA. Reduced capillary perfusion and permeability in human tumour xenografts treated with the VEGF signalling inhibitor ZD4190: an in vivo assessment using dynamic MR imaging and macromolecular contrast media. Magn Reson Imaging. 2003 Oct;21(8):845-51. doi: 10.1016/s0730-725x(03)00186-3. PMID: 14599534. 9: Checkley D, Tessier JJ, Wedge SR, Dukes M, Kendrew J, Curry B, Middleton B, Waterton JC. Dynamic contrast-enhanced MRI of vascular changes induced by the VEGF-signalling inhibitor ZD4190 in human tumour xenografts. Magn Reson Imaging. 2003 Jun;21(5):475-82. doi: 10.1016/s0730-725x(02)00644-6. PMID: 12878256. 10: Clément O, Pradel C, Siauve N, Frouin F, Bruneteau G, Kahn E, Frija G, Cuénod CA. Assessing perfusion and capillary permeability changes induced by a VEGF inhibitor in human tumor xenografts using macromolecular MR imaging contrast media. Acad Radiol. 2002 Aug;9 Suppl 2:S328-9. doi: 10.1016/s1076-6332(03)80219-2. PMID: 12188264. 11: Wedge SR, Ogilvie DJ. Inhibition of VEGF signal transduction. Identification of ZD4190. Adv Exp Med Biol. 2000;476:307-10. doi: 10.1007/978-1-4615-4221-6_25. PMID: 10949675. 12: Wedge SR, Ogilvie DJ, Dukes M, Kendrew J, Curwen JO, Hennequin LF, Thomas AP, Stokes ES, Curry B, Richmond GH, Wadsworth PF. ZD4190: an orally active inhibitor of vascular endothelial growth factor signaling with broad-spectrum antitumor efficacy. Cancer Res. 2000 Feb 15;60(4):970-5. PMID: 10706112.